MDMB-FUBICA is an
indole
Indole is an organic compound with the formula . Indole is classified as an aromatic heterocycle. It has a bicyclic structure, consisting of a six-membered benzene ring fused to a five-membered pyrrole ring. Indoles are derivatives of indole ...
-based
synthetic cannabinoid
Synthetic cannabinoids, or neocannabinoids, are a class of designer drug molecules that Binding affinity, bind to the same receptors to which cannabinoids (Tetrahydrocannabinol, THC, Cannabidiol, CBD and many others) in cannabis plants attach. Th ...
that is presumed to be a potent
agonist
An agonist is a chemical that activates a Receptor (biochemistry), receptor to produce a biological response. Receptors are Cell (biology), cellular proteins whose activation causes the cell to modify what it is currently doing. In contrast, an R ...
of the
CB1 receptor and has been sold online as a
designer drug
A designer drug is a structural or functional analog of a controlled substance that has been designed to mimic the pharmacological effects of the original drug, while avoiding classification as illegal and/or detection in standard drug tests. ...
.
It was first detected by the
EMCDDA
The European Union Drugs Agency (EUDA), known until 2024 as the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), is an agency of the European Union headquartered in Lisbon, Portugal, and established in 1993.
In June 2022, the ...
in Sweden in February 2015. It is often sold in
e-liquid
An electronic cigarette is a handheld battery-powered vaporizer that simulates smoking, but without tobacco combustion. E-cigarette components include a mouthpiece (drip tip), a cartridge (liquid storage area), a heating element/ atomizer, a m ...
form for use in an
electronic cigarette
An electronic cigarette (e-cigarette), or vape, is a device that simulates smoking. It consists of an atomizer, a power source such as a battery, and a container such as a cartridge or tank. Instead of smoke, the user inhales vapor. As such ...
.
Side effects
MDMB-FUBICA's indazole analogue
MDMB-FUBINACA
MDMB-FUBINACA (also known as MDMB(N)-Bz-F and FUB-MDMB) is an indazole-based synthetic cannabinoid that is a potent agonist for cannabinoid receptors and that has been sold online as a designer drug. The structure of MDMB-FUBINACA contains the ...
has been linked to at least 1000 hospitalisations and 40 deaths as a consequence of intoxication as of March 2015.
Legality
MDMB-FUBICA is banned in Sweden.
See also
*
5F-AB-PINACA
*
5F-ADB
5F-ADB (also known as MDMB-5F-PINACA using systematic EMCDDA nomenclature and 5F-MDMB-PINACA) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family, which has been used as an active ingredient in synthetic cannabis ...
*
5F-AMB
5F-AMB (also known as 5F-MMB-PINACA and 5F-AMB-PINACA) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family, which has been used as an active ingredient in synthetic cannabis products. It was first identified in Jap ...
*
5F-APINACA
5F-APINACA (also known as A-5F-PINACA, 5F-AKB-48 or 5F-AKB48) is an indazole-based synthetic cannabinoid that has been sold online as a designer drug. Structurally it closely resembles cannabinoid compounds from patent WO 2003/035005 but with ...
*
AB-FUBINACA
AB-FUBINACA ( AMB-FUBINACA) is a psychoactive drug that acts as a potent agonist for the cannabinoid receptors, with ''K''i values of 0.9 nM at CB1 and 23.2 nM at CB2 and EC50 values of 1.8 nM at CB1 and 3.2 nM at CB2. I ...
*
AB-CHFUPYCA
AB-CHFUPYCA (also AB-CHMFUPPYCA) is a compound that was first identified as a component of synthetic cannabis products in Japan in 2015. The name "AB-CHFUPYCA" is an acronym of its systematic name ''N''-(1-Amino-3-methyl-1-oxoButan-2-yl)-1-(Cycl ...
*
AB-CHMINACA
*
AB-PINACA
AB-PINACA is a compound that was first identified as a component of synthetic cannabis products in Japan in 2012.
It was originally developed by Pfizer in 2009 as an analgesic medication.
AB-PINACA acts as a potent agonist for the CB1 recepto ...
*
ADB-CHMINACA
ADB-CHMINACA (also known as ADMB-CHMINACA and MAB-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of ''K''i = 0.289 nM and was originally developed by Pfiz ...
*
ADB-FUBINACA
ADB-FUBINACA (ADMB-FUBINACA) is a designer drug identified in synthetic cannabis blends in Japan in 2013. In 2018, it was the third-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration.
The name ...
*
ADB-PINACA
ADB-PINACA is a cannabinoid designer drug that is an ingredient in some synthetic cannabis products. It is a potent agonist of the CB1 receptor and CB2 receptor with EC50 values of 0.52 nM and 0.88 nM respectively. Like MDMB-FUBIN ...
*
AMB-FUBINACA
AMB-FUBINACA (also known as FUB-AMB and MMB-FUBINACA) is an indazole-based synthetic cannabinoid that is a potent agonist for the cannabinoid receptors, with ''K''i values of 10.04 nM at CB1 and 0.786 nM at CB2 and EC50 values of ...
*
APINACA
APINACA (AKB48, ''N''-(1-adamantyl)-1-pentyl-1''H''-indazole-3-carboxamide) is a drug that acts as a reasonably potent agonist for the cannabinoid receptors. It is a full agonist at CB1 with an EC50 of 142 nM and Ki of 3.24 nM (compared to the ...
*
APP-FUBINACA
APP-FUBINACA is an indazole-based synthetic cannabinoid that has been sold online as a designer drug. Pharmacological testing showed APP-FUBINACA to have only moderate affinity for the CB1 receptor, with a Ki of 708 nM, while its EC50 was not t ...
*
FUB-APINACA
*
MDMB-CHMICA
MDMB-CHMICA is an indole-based synthetic cannabinoid that is a potent agonist of the CB1 receptor and has been sold online as a designer drug. While MDMB-CHMICA was initially sold under the name "MMB-CHMINACA", the compound corresponding to thi ...
*
MDMB-CHMINACA
MDMB-CHMINACA (also known as MDMB(N)-CHM) is an indazole-based synthetic cannabinoid that acts as a potent agonist of the CB1 receptor, and has been sold online as a designer drug. It was invented by Pfizer in 2008, and is one of the most pote ...
*
PX-3
PX-3 (also known as APP-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of ''K''i = 47.6 nM and was originally developed by Pfizer in 2009 as an analgesic m ...
References
Cannabinoids
Designer drugs
Indolecarboxamides
4-Fluorophenyl compounds
{{cannabinoid-stub